NEHI Vaccine Summit: Looming Challenges of COVID-19 Immunization: Moving Forward
January 27 @ 1:00 pm - 2:00 pm
The fourth in a NEHI series of virtual summit meetings on COVID-19 Immunization
COVID-19 vaccines are key to ending the pandemic. Now that two vaccines have received Emergency Use Authorizations, and with several other promising vaccines close behind, vaccine distribution, administration and uptake have become critical.
Join NEHI on Wednesday, January 27th for the final summit in its Looming Challenges of COVID-19 Immunization Series. The Summit will focus on successes, challenges, and future plans with respect to COVID-19 immunizations.
Our expert panel will share their initial experiences with vaccine administration and discuss their strategies as the COVID vaccines become available to broader populations in the second and third phases of the immunization campaign. Hear how the Directors of Immunization in Louisiana and Indiana, representatives from Kaiser Permanente and Geisinger Health, and others are addressing the challenges of building vaccine confidence, tracking local immunization status, ensuring uptake of both vaccine doses, and more.
NEHI is pleased to announce that Dan Barouch, MD, PhD is the keynote speaker of the Summit. Dr. Dan Barouch is currently the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery. His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies. His group has also applied their vaccine expertise to preclinical and clinical studies of other infectious diseases of global significance, including Zika virus, tuberculosis, and most recently SARS-CoV-2. Dr. Barouch is a lead researcher on the Johnson & Johnson vaccine candidate, which offers the potential to be a single dose vaccine. Johnson & Johnson announced their phase 3 trials are fully enrolled with 45,000 people and hopes to submit an EUA application with the FDA in February.